Shionogi & Company, Limited (塩野義製薬株式会社, Shionogi Seiyaku Kabushiki Kaisha) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).
 | |
Native name | 塩野義製薬株式会社 |
|---|---|
Romanized name | Shionogi Seiyaku Kabushiki Kaisha |
| Company type | Public (K.K) |
| TYO: 4507 Nikkei 225 Component | |
| Industry | Biotechnology & Pharmaceuticals |
| Founded | Osaka, Japan (March 17, 1878) |
| Founder | Gisaburo Shiono Sr. |
| Headquarters | 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan |
Key people | |
| Products | |
| Revenue |  ¥ 426.684 billion (2022)[1] |
| ¥ 133.274 billion (2022)[1] | |
| ¥ 107.367 billion (2022)[1] | |
| Total assets | ¥ 768.120 billion (2022)[1] |
| Total equity | ¥ 1,121.878 billion (2022)[1] |
Number of employees | Consolidated : 6,082 |
| Website | Official website |
| Footnotes / references [2][3][1] | |
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.[4]
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.[5]
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.[6]
Medicines
editReleased
edit- Avelox, antibacterial antiseptic that treats a number of infections.
- Claritin, An anti-histamine marketed in alliance with Schering-Plough.
- Crestor, cholesterol drug
Shionogi Headquarters in Osaka - Cymbalta, an SNRI class anti-depressant, marketed in alliance with Eli Lilly.
- Differin (developed by Galderma), a topical retinoid for acne, marketed in Japan in alliance with Galderma.
- Fortamet
- Methylin
- Mogadon, a short-term treatment for insomnia.
- Mulpleta, a thrombopoietin receptor agonist.
- Osphena, an estrogen receptor agonist, marketing rights sold to Duchesnay in 2017.[9]
- Symproic, a μ-opioid receptor antagonist, for opioid-induced constipation treatment.
- Xofluza, an endonuclease inhibitor, for influenza treatment.
- Ensitrelvir, the first Japanese domestic pill to treat COVID-19.[10]
Under development
edit- Asapiprant (BGE-175), a DP1 receptor antagonist under development for treatment of COVID-19 in elderly patients and allergic rhinitis.[11][12][13][14][15]
Media
edit- Shionogi has a close relationship with Fuji Television Network, Inc., because Shionogi is the sponsor of "Music Fair" (as of January 2010, aired on 17 TV stations including TV Oita System Co.) started in 1964.[citation needed]
- Shionogi was a main sponsor of Team Lotus in the team's final years between 1991 and 1994.[16]
References
edit- ^ a b c d e f "Consolidated Financial Results for Fiscal Year 2022 (IFRS)" (PDF). 23 February 2023. Retrieved 27 June 2023.
- ^ "Shionogi Company Profile". Archived from the original on 28 January 2020. Retrieved 18 March 2014.
- ^ "Shionogi Annual Report 2013" (PDF). Archived (PDF) from the original on 11 July 2019. Retrieved 18 March 2014.
- ^ "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". viivhealthcare.com. Archived from the original on 7 March 2014. Retrieved 18 March 2014.
- ^ "Components:Nikkei Stock Average". Nikkei Inc. Archived from the original on 14 November 2016. Retrieved 11 March 2014.
- ^ BioSpace (27 June 2023). "Shionogi buys Qpex Biopharma for $140M, expands antimicrobial pipeline – PharmaLive". Retrieved 27 June 2023.
- ^ Du, Lisa (7 October 2021). "Covid Pill Sales Could Hit $2 Billion, Japan's Shionogi Says". Bloomberg. Retrieved 21 March 2022.
- ^ Du, Lisa (22 February 2010). "AstraZeneca begins court fight over Crestor patent". Reuters. Retrieved 21 March 2022.
- ^ "Duchesnay acquires Osphena from Shionogi Inc" (Press release). Duchesnay. 10 March 2017. Archived from the original on 24 October 2019. Retrieved 23 October 2019.
- ^ "Japan's Shionogi seeks approval for COVID-19 pill". Reuters. Reuters. 25 February 2022.
- ^ "Notice regarding an initiation of Phase 2 clinical trial by BioAge aimed at treating older patients of COVID-19" (PDF) (Press release). Retrieved 21 March 2022.
- ^ "Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure". ClinicalTrials.gov. Retrieved 21 March 2022.
- ^ Wong, Lok-Yin (21 March 2022). "Eicosanoid signaling blockade protects middle-aged mice from severe COVID-19". Nature. 605 (7908): 146–151. Bibcode:2022Natur.605..146W. doi:10.1038/s41586-022-04630-3. PMC 9783543. PMID 35314834. S2CID 247597933.
- ^ Swift, Rocky (26 January 2021). "Japan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge".
- ^ "New BioAge Drug Prevents Death From COVID-19 in Old Mice by Reversing Immune Aging" (Press release). BioAge Labs. SciTech (magazine). Retrieved 21 March 2022.
- ^ Perry, Alan. "Sponsor Company Profiles". Archived from the original on 17 June 2013. Retrieved 25 April 2012.
External links
edit
- Official Website (in English)
- Official U.S. Website (in English)